Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Today, WHO and HRP have launched a new guideline to help countries make faster progress, more equitably, on the screening and treatment of this devastating disease.

On July 9th, Roche Diagnostics Asia-Pacific production base and R&D center built another new manufacturing building-System Reagent Manufacturing Base. It was officially completed in Suzhou Industrial Park. The total investment in the project is 390 million yuan.

Recently, it was learned from Shanghai Fosun Pharma officially signed a sales agreement with TSMC, FOXCONN, YongLin, and Zuellig Pharma, respectively, to sell a total of 10 million doses of COVID-mRNA vaccine. This batch of vaccine will be donated to local vaccination in Taiwan.

On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena.

Quidel has issued a recall for certain lots of its Lyra brand SARS-CoV-2 tests due to the potential for false negative results in patient samples with relatively high amounts of virus.

Global life sciences leader Cytiva has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Cytiva will use Intermountain’s manufacturing site in Utah to rapidly boost its liquid cell culture production by millions of liters.

On June 30, Sichuan Orienter Biotechnology Co., Ltd. and InTec PRODUCTS INC. applied for the Growth Enterprise Market and was accepted by Shenzhen Stock Exchange.

The US Food and Drug Administration recently granted separate Emergency Use Authorization for molecular SARS-CoV-2 tests from Exact Sciences and BioGx, an immunoassay for detecting the virus from Bio-Rad Laboratories, and an at-home specimen collection kit from Everlywell.

NEW YORK – Qiagen said on Thursday that it has formed a global strategic alliance with Japan's Sysmex to develop and commercialize cancer companion diagnostics using Sysmex's Plasma-Safe-SeqS next-generation sequencing technology.

On the evening of June 30, it is said that Hotgen Biotech will increase by about ￥1.378 billion yuan to about ￥1.598 billion yuan, with a year-on-year increase of 70546.05% to 81808.47% ,which is Compared with the same period of last year.